AB Science plummets as EU frowns on cancer drug

France's AB Science watched its shares tank as much as 31% on Friday after a European Medicines Agency panel rejected its gastrointestinal cancer treatment, casting serious doubts on the drug's potential approval. The Committee for Medicinal Products for Human Use (CHMP) ruled against masitinib, a treatment currently used on dogs, and AB Science is appealing the decision, hoping to address the panel's concerns and get a second vote next year. Article

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.